V1RG4 Inhibitors
V1RG4 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the V1RG4 protein, which is a component of the vacuolar-type H+-ATPase (V-ATPase) complex. The V-ATPase is a multi-subunit enzyme complex responsible for generating a proton gradient across membranes in various intracellular compartments, such as endosomes, lysosomes, and vacuoles. The V1RG4 protein is a part of the V1 domain of this complex, which is integral to the hydrolysis of ATP, the process that powers the proton pump. This domain is crucial for the assembly and operation of the V-ATPase, ensuring that it can effectively transport protons across cellular membranes and maintain the acidic environment necessary for various cellular processes.
The primary action of V1RG4 inhibitors involves binding specifically to the V1RG4 protein and disrupting its function within the V1 domain of the V-ATPase complex. By targeting V1RG4, these inhibitors can interfere with the assembly, stability, or activity of the V1 domain, thereby impairing the complex's ability to hydrolyze ATP and pump protons. This inhibition affects the proton gradient and pH balance within the intracellular compartments that rely on V-ATPase activity. Studying V1RG4 inhibitors offers valuable insights into the role of V1RG4 in V-ATPase function and helps elucidate how disruptions in this protein impact cellular pH regulation and proton transport mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to intracellular calcium depletion, which may downregulate V1R76 expression. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is a calcium chelator that reduces intracellular calcium levels, potentially inhibiting the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Cyclopiazonic acid inhibits SERCA, leading to intracellular calcium depletion, which may downregulate V1R76 expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $184.00 $245.00 | 13 | |
Ruthenium Red is a calcium channel blocker that inhibits calcium influx, potentially interfering with the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $500.00 | 14 | |
Xestospongin C inhibits IP3 receptor-mediated calcium release from the endoplasmic reticulum, potentially downregulating V1R76 expression. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB inhibits IP3 receptor-mediated calcium release from the endoplasmic reticulum, potentially downregulating V1R76 expression. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $101.00 $155.00 $389.00 $643.00 | 2 | |
SKF-96365 inhibits store-operated calcium entry (SOCE), potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||
Gadolinium(III) chloride | 10138-52-0 | sc-224004 sc-224004A | 5 g 25 g | $150.00 $350.00 | 4 | |
Gadolinium chloride inhibits non-selective cation channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R76 expression. | ||||||